Literature DB >> 31071696

Assessment of microcirculation in the diabetic foot with laser speckle contrast imaging.

O A Mennes1, J J van Netten, J G van Baal, W Steenbergen.   

Abstract

OBJECTIVE: A major challenge for treating diabetic foot ulcers is estimating the severity of ischemia, as the currently used non-invasive diagnostic techniques provide relatively poor prognostic values. Laser speckle contrast imaging (LSCI) is a promising non-invasive technique to assess microcirculation. Our aim was to investigate the stability and reproducibility of LSCI for the assessment of microcirculation in the diabetic foot, the relation of LSCI results to currently used non-invasive blood pressure measurements, and the ability of LSCI to discriminate between the degrees of ischemia. APPROACH: Thirty-three participants with diabetic foot ulcers were included in this prospective, single centre, observational cohort study that was conducted in the Netherlands. They were classified as non-ischemic, ischemic or critical-ischemic based on criteria formulated in the international guidelines. Two clinicians performed LSCI scans of the foot, consisting of baseline measurements, followed by two stress tests (post-occlusion peak and elevation test). With three measurement conditions and five regions of interest of the foot per patient, a total of 15 measurements were available for analyses. MAIN
RESULTS: The intra-observer agreement of LSCI was high (interclass correlation coefficient (ICC)  =  0.711-0.950; p   <  0.001) for all 15 measurements. The inter-observer agreement was high (ICC  =  0.728-0.861; p   ⩽  0.001) for 10 measurements and moderate (ICC  =  0.476-0.570; p   ⩽  0.005) for the remaining five measurements. The inter-assessor agreement was high and significant (ICC  =  0.857-0.996; p   ⩽  0.001) for all measurements. Correlation between LSCI and non-invasive blood pressure measurements was low (ICC  =  -0.272-0.582). During both stress tests, microcirculation was significantly lower in critical-ischemic feet compared to non-ischemic feet (67.5 perfusion units (PU) versus 96.3 PU and 41.0 PU versus 63.9 PU; p   <  0.05). SIGNIFICANCE: LSCI is a stable and reproducible technique for assessment of microcirculation in people with diabetic foot ulcers and shows significant differences between non-ischemic, ischemic and critical-ischemic patient populations.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31071696     DOI: 10.1088/1361-6579/ab2058

Source DB:  PubMed          Journal:  Physiol Meas        ISSN: 0967-3334            Impact factor:   2.833


  5 in total

1.  Multi-scale laser speckle contrast imaging of microcirculatory vasoreactivity.

Authors:  Blaire Lee; Olga Sosnovtseva; Charlotte M Sørensen; Dmitry D Postnov
Journal:  Biomed Opt Express       Date:  2022-03-21       Impact factor: 3.562

Review 2.  Methods to evaluate vascular function: a crucial approach towards predictive, preventive, and personalised medicine.

Authors:  Cristina M Sena; Lino Gonçalves; Raquel Seiça
Journal:  EPMA J       Date:  2022-05-20       Impact factor: 8.836

3.  Semi-Automatic Tracking of Laser Speckle Contrast Images of Microcirculation in Diabetic Foot Ulcers.

Authors:  Onno A Mennes; Mark Selles; Jaap J van Netten; Jeff G van Baal; Wiendelt Steenbergen; Riemer H J A Slart
Journal:  Diagnostics (Basel)       Date:  2020-12-06

4.  Haemodialysis and peritoneal dialysis patients have severely impaired post-occlusive skin forearm vasodilatory response assessed with laser speckle contrast imaging.

Authors:  Maria-Eleni Alexandrou; Εugenia Gkaliagkousi; Charalampos Loutradis; Chrysostomos Dimitriadis; Efstathios Mitsopoulos; Antonios Lazaridis; Barbara Nikolaidou; Panagiotis Dolgiras; Stella Douma; Aikaterini Papagianni; Pantelis A Sarafidis
Journal:  Clin Kidney J       Date:  2020-10-21

5.  Transmissive-detected laser speckle contrast imaging for blood flow monitoring in thick tissue: from Monte Carlo simulation to experimental demonstration.

Authors:  Dong-Yu Li; Qing Xia; Ting-Ting Yu; Jing-Tan Zhu; Dan Zhu
Journal:  Light Sci Appl       Date:  2021-12-03       Impact factor: 17.782

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.